This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

AGIL-FA

Agilis Biotherapeutics, Inc.

Drug Names(s): FXN Gene Therapy

Description: AADC Gene Therapy is an investigative gene therapy with adeno-associated virus (AAV) delivering the frataxin (FXN) gene.

Deal Structure: Agilis and Intrexon
In 2013, Agilis and Intrexon executed an exclusive channel collaboration through which Agilis intends to develop and commercialize novel DNA-based therapeutics for the treatment of Friedreich's ataxia. Under the ECC Agilis also has an option to expand its relationship with Intrexon by adding another rare genetic disease to the collaboration.

Partners: Intrexon Corporation


AGIL-FA News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug